|
PHC3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.94393415095828E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.80400000388192E-09 |
| Normal-vs-Stage2 |
3.14380000032699E-07 |
| Normal-vs-Stage3 |
4.1115999493968E-11 |
| Normal-vs-Stage4 |
3.27390003995731E-09 |
| Stage1-vs-Stage2 |
4.073600E-01 |
| Stage1-vs-Stage3 |
6.783600E-02 |
| Stage1-vs-Stage4 |
5.984200E-02 |
| Stage2-vs-Stage3 |
6.181200E-01 |
| Stage2-vs-Stage4 |
5.021600E-01 |
| Stage3-vs-Stage4 |
8.028800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.80580003675368E-11 |
| Normal-vs-AfricanAmerican |
9.156600E-03 |
| Normal-vs-Asian |
5.22680000392128E-08 |
| Caucasian-vs-AfricanAmerican |
1.200570E-01 |
| Caucasian-vs-Asian |
8.240600E-01 |
| AfricanAmerican-vs-Asian |
1.413790E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.14660003713851E-09 |
| Normal-vs-Female |
2.25619967153534E-10 |
| Male-vs-Female |
2.381400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.00599999944373E-08 |
| Normal-vs-Age(41-60Yrs) |
5.7421001287139E-10 |
| Normal-vs-Age(61-80Yrs) |
1.24280030711077E-10 |
| Normal-vs-Age(81-100Yrs) |
6.362200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.236000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.166200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.126400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.180800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.282200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.262000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.441900E-04 |
| Classical-VS-Follicular |
2.846200E-01 |
| Classical-VS-Other |
2.817200E-01 |
| Classical-VS-Normal |
4.28239999017421E-10 |
| Tall-VS-Follicular |
7.031800E-02 |
| Tall-VS-Other |
7.223200E-01 |
| Tall-VS-Normal |
1.64150026904508E-10 |
| Follicular-VS-Other |
6.150600E-01 |
| Follicular-VS-Normal |
2.81179999950254E-07 |
| Other-VS-Normal |
2.838300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.28741503305719E-12 |
| Normal-vs-N1 |
1.20910000012131E-07 |
| N0-vs-N1 |
9.150600E-01 |
|
|
